Burnusuzov Hasan A, Spasova Mariya I, Murdjeva Mariana A, Stoyanova Angelina A, Mumdziev Ivan N, Kaleva Valeriya I, Belcheva Milena I, Bosheva Miroslava N
Department of Pediatrics and Medical Genetics, Medical University of Plovdiv, Plovdiv, Bulgaria
Department of Microbiology and Immunology, Medical University of Plovdiv, Plovdiv, Bulgaria
Folia Med (Plovdiv). 2016 Mar 1;58(1):28-35. doi: 10.1515/folmed-2016-0004.
Early clearance of leukemic cells during induction therapy of childhood acute lymphoblastic leukemia (ALL) is a basis for treatment optimization. Currently, the most widely used methods for the detection of minute residual malignant cells in the bone marrow and/or peripheral blood, minimal residual disease (MRD), are PCR and flow cytometry (FCM). Immunophenotypic modulation (IM) is a well known factor that can hamper the accurate FCM analysis.
To report the IM detected by 8-color FCM during the BFM-type remission induction in 24 consecutive MRD-positive samples of children with B-cell precursor ALL and the possible implications for MRD detection.
Between 2010 and 2012 we prospectively followed up the MRD on days 15 and 33 of induction treatment in bone marrow (BM) samples and on day 8 in peripheral blood (PB). The IM was assessed by comparative analyses of the changes in the mean fluorescence intensity of 7 highly relevant antigens expressed by the leukemic cells and normal B-lymphocytes.
IM occurred, to different extents, in all analyzed day 15 BM and in most day 33 BM samples. Statistically significant changes in the MFI-levels of four CDs expressed by the leukemic blasts were observed: downmodulation of CD10, CD19 and CD34 and upmodulation of CD20. No changes in the expression of CD38, CD58 and CD45 were noticed.
Measuring the MRD by standardized 8-color flow cytometry helps improve the monitoring of the disease, leading to better therapeutic results. However, the IM of the different antigens expressed by the leukemic blasts should be taken into consideration and cautiously analyzed.
儿童急性淋巴细胞白血病(ALL)诱导治疗期间白血病细胞的早期清除是优化治疗的基础。目前,用于检测骨髓和/或外周血中微小残留恶性细胞,即微小残留病(MRD)的最广泛使用的方法是聚合酶链反应(PCR)和流式细胞术(FCM)。免疫表型调制(IM)是一个众所周知的会妨碍准确FCM分析的因素。
报告在24例B细胞前体ALL患儿的连续MRD阳性样本的BFM型缓解诱导期间通过8色FCM检测到的IM及其对MRD检测的可能影响。
在2010年至2012年期间,我们前瞻性地随访了诱导治疗第15天和第33天骨髓(BM)样本以及第8天外周血(PB)中的MRD。通过对白血病细胞和正常B淋巴细胞表达的7种高度相关抗原的平均荧光强度变化进行比较分析来评估IM。
在所有分析的第15天骨髓样本以及大多数第33天骨髓样本中均不同程度地出现了IM。观察到白血病原始细胞表达的四种CD的平均荧光强度水平有统计学意义的变化:CD10、CD19和CD34下调,CD20上调。未注意到CD38、CD58和CD45表达的变化。
通过标准化的8色流式细胞术测量MRD有助于改善疾病监测,从而带来更好的治疗效果。然而,应考虑并谨慎分析白血病原始细胞表达的不同抗原的IM。